Luo X, Keller MA, James I, et al. Strategies to identify candidates for D variant genotyping. Blood Transfus 2018;16:293–301.Search in Google Scholar
Denomme GA, Wagner FF, Fernandes BJ, et al. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005;45:1554–60.Search in Google Scholar
Wagner FF, Frohmajer A, Ladewig B, et al. Weak D alleles express distinct phenotypes. Blood 2000;95:2699–708.Search in Google Scholar
Denomme G, Dake L, Vilensky D, Ramyar L, Judd W. Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques. Transfusion 2008;48:473–8.Search in Google Scholar
Judd WJ, Moulds M, Schlanser G. Reactivity of FDA-approved anti-D reagents with partial D red blood cells. Immunohematology 2005;21:146–8.Search in Google Scholar
Cohn CS, Delaney M, Johnson ST, Katz LM, Schwartz J. Technical manual. 21st ed. Bethesda, MD: AABB, 2023.Search in Google Scholar
Sandler SG, Flegel WA, Westhoff CM, et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion 2015;55:680–9.Search in Google Scholar
Daniels, Geoff. Variants of RhD—current testing and clinical consequences. Br J Haemato 2013;161:461–70.Search in Google Scholar
Flegel WA, Denomme GA, Queenan JT, et al. It’s time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4. Transfusion 2020;60;855–9.Search in Google Scholar
Barriteau C, Lindholm P, Hartman K, Sumugod R, Ramsey G. RHD genotyping to resolve weak and discrepant RhD patient phenotypes. Transfusion 2022;62:2194–9.Search in Google Scholar
Horn TN, Keller J, Keller MA, Klinger L. Identifying obstetrics patients in whom RHD genotyping can be used to assess risk of D alloimmunization. Immunohematology 2020;36:146–51.Search in Google Scholar
Hudgens JP, Matsushita C, Tuma CW, O’Brien L, Shulman IA. Identification of RHD allelic variants discovered by atypical typing results on the NEO/Echo platforms. Am J Clin Pathol 2021;156:1000–6.Search in Google Scholar
Juhl D, Luckner, K, Brockmann C, et al. RHD-negative red cells may be avoided for patients with ambiguous serologic typing for the RHD antigen. Transfusion 2024;64:281–8.Search in Google Scholar
Pham B-N, Roussel M, Peyrard T, et al. Anti-D investigations in individuals with weak D type 1 or 2 individuals. Transfusion 2011;51:2679–85.Search in Google Scholar
Noizat-Pirenne F, Verdier M, Lejealle A, et al. Weak D phenotypes and transfusion safety: where do we stand in daily practice? Transfusion 2007;47:1616–20.Search in Google Scholar
Westhoff CM, Vege S, Halter-Hipsky C, et al. DIIIa and DIII type 5 are encoded by the same allele and are associated with altered RHCE*ce alleles: clinical implications. Transfusion 2010;50:1303–11.Search in Google Scholar
Gassner C, Doescher A, Drnovsek TD, et al. Presence of RHD in serologically D–, C/E+ individuals: a European multicenter study. Transfusion 2005;45:527–38.Search in Google Scholar
St-Louis M, Richard M, Côté M, Ethier C, Long A. Weak D type 42 cases found in individuals of European descent. Immunohematology 2011;27:20–4.Search in Google Scholar
Chiu RW, Murphy MF, Fidler C, Zee BC, Wainscoat JS, Lo YM. Determination of RhD zygosity: comparison of a double amplification refractory mutation system approach and a multiplex real-time quantitative PCR approach. Clin Chem 2001;47:667–72.Search in Google Scholar
Code of Federal Regulations. Testing the blood. 21 CFR 640 640.5 2024. Available from https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493. Accessed 22 January 2023.Search in Google Scholar
